Thankyou for the interesting read
It’s hard to say why a drop in sales. I’m certain it won’t be to do with the effectiveness or safety of the DAAs we have taken or are taking or for some, about to take. Like Meg I researched the new drug but information is sketchy.

Interesting snippets from this pdf include Gilead stating “….the potential pricing pressure from additional competitive HCV launches or austerity measures in European Countries and Japan…..”

I’m still arguing the generic case and recoil at Gileads profit margins as we all do.
Another useful doc ty ROhcv for this
Cheers from Ariel

I also read that insurance companies continue to limit access to only the sickest patients, and that many are given only 8 weeks of treatment (less than 6 million VL) that is also cutting in to earnings.

Gilead’s share price is down 32% from a peak of $122.21 on 23 June 2015 pre generics to $83.62 today – post generics.

Current market cap of $112 billion was $164 billion last year, so $52 billion dollars worth of greed has now dissolved before investors eyes.

$50 billion – that’s $50,000,000,000 in investor losses, and last year 500,000 patients died of a now curable illness.

Coincidentally it works out at an investor loss of $100,000 per patient death, more or less exactly the same as the cost per cure.

Karma?

A lot of factors could be contributing to this decline in “blood money”.
I would like to think generics is a major one.
m

It seems to me the only way these prices will ever come down, is to make a legal case that these companies are ‘profiteering’ or ‘price gouging’.

Seems a lot of politicians are either corrupt or cowards.

I’m sure there were quite a few people with enough money just to self-pay when Harvoni first came out. The “Pamela Andersons” and other financially blessed suffers just bought it.
m

Gilead stock is currently trading at $83.04, down from $123.57 a year ago. A lot of things have happened since last June:
As I mentioned earlier, the people who had the money in the US, bought Harvoni as soon as it became available. That market is pretty much gone.
The insurers covered many of the sickest patients early on. There are a lot of really sick people who don’t have insurance or have bad insurance coverage, however. Many are still waiting for access to treatment.
The competition has increased, forcing Gilead to negotiate lower prices for insurance companies as well as entire countries. Australia is a good example.
In addition, generics have come into play. I imagine the health tourism business in India is flourishing.
There are other factors I’m sure, but Gilead’s share price seems to have stabilized around $80.00. I imagine it will stay there until someone comes up with a much shorter treatment regimen.
m